文献速递特殊人群用药治疗药物监测与药物基因组学

基于机制的群体药代动力学分析评估孕妇依非韦伦减至400mg的可行性

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

该研究利用7项研究汇总数据(1968份样本,其中774份孕期采集)构建机制性群体药代动力学模型,预测孕妇与非孕妇使用400mg和600mg依非韦伦的总量和游离药物暴露。结果显示,孕晚期400mg剂量下总量AUC24和C12中位数分别为非孕妇的91%和87%,游离C12和AUC24中位数分别增加11%和15%,提示减量方案在孕期可提供充足暴露,但需前瞻性验证。

要点

  • 孕晚期使用400mg依非韦伦时总量暴露约为非孕妇的87%-91%。
  • 孕期游离依非韦伦C12和AUC24中位数分别增加11%和15%。
  • 减量至400mg在孕期可能提供充足暴露,尚需前瞻性确认。

核心结论

  • 预测表明减量至400mg的依非韦伦在孕期可提供充足暴露,这些发现需要前瞻性确认。

研究设计与样本

  • 采用机制性群体药代动力学模型,汇总7项研究数据,共1968份样本,其中774份采集于孕期。

主要发现

  • 使用400mg剂量时,孕晚期依非韦伦总量AUC24和C12中位数分别为非孕妇的91%和87%。
  • 孕期游离依非韦伦C12和AUC24中位数预测分别增加11%和15%。

局限性

  • 研究为预测性分析,结论尚需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reducing the dose of efavirenz can improve safety, reduce costs, and increase access for patients with HIV infection. According to the World Health Organization, a similar dosing strategy for all patient populations is desirable for universal roll-out; however, it remains unknown whether the 400 mg daily dose is adequate during pregnancy. METHODS: We developed a mechanistic population pharmacokinetic model using pooled data from women included in seven studies (1968 samples, 774 collected during pregnancy). Total and free efavirenz exposure (AUC24 and C12) were predicted for 400 (reduced) and 600 mg (standard) doses in both pregnant and non-pregnant women. RESULTS: Using a 400 mg dose, the median efavirenz total AUC24 and C12 during the third trimester of pregnancy were 91 and 87% of values among non-pregnant women, respectively. Furthermore, the median free efavirenz C12 and AUC24 were predicted to increase during pregnancy by 11 and 15%, respectively. CONCLUSIONS: It was predicted that reduced-dose efavirenz provides adequate exposure during pregnancy. These findings warrant prospective confirmation.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Schalkwijk S, Ter Heine R, Colbers AC, et al. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clin Pharmacokinet. 2018. PMID: 29520730. doi:10.1007/s40262-018-0642-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。